Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2007-10-12

Clinical Trial Update: FIM-NL - First-in-Man Study (Netherlands Part) With Sirolimus Coated Modified BX Velocity Stent [Phase 1, Phase 2]

View source ↗

Summary

Completion of a first-in-man Phase 1/2 Netherlands study evaluating a sirolimus-coated BX Velocity coronary stent.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rapamune (sirolimus)

Snippet

Sponsor: Cordis US Corp. | Conditions: Coronary Artery Disease | Phase 1, Phase 2 | Status: COMPLETED